Guardant Health (GH) Stock Could Be Undervalued Despite Its 5x Run
Simply Wall Street
Guardant Health (GH) has seen its stock increase fivefold over the past three years, prompting questions about whether its current valuation is supported by future cash flows. The company's recent expansion of coverage for its Shield blood test is expected to boost future cash inflows significantly, with analysts forecasting a move from current cash burning to substantial free cash generation by the early 2030s, which could justify its current share price of $177.25. However, there are differing
Read the full story
This is a short summary. The complete article is published by Simply Wall Street.
Headline and summary aggregated from public news feeds. For information only — not financial advice.